CMS specialty measure sets may be reported as an alternative to reporting 6 separate quality measures. If a measure set has less than 6 measures, eligible groups and clinicians must report all measures in the set. However, if a set has more than 6 measures, participants may choose the 6 measures that best fit their practice. Remember, at least one outcome measure must be reported, regardless of whether or not an outcome measure is included in a measure set.
|Quality Id||Measure Name||High Priority||Measure Type||Measure Description||hf:tax:specialty_measure_sets||hf:tax:collection_types|
|130||2022 Measure # 130 Documentation of Current Medications in the Medical Record||yes||Process||Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications’ name, dosage, frequency and route of administration||Details|
|138||2022 Measure # 138 Melanoma: Coordination of Care||yes||Process||Percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis||Details|
|176||2022 Measure # 176 Tuberculosis Screening Prior to First Course Biologic Therapy||no||Process||If a patient has been newly prescribed a biologic disease-modifying anti-rheumatic drug (DMARD) therapy, then the medical record should indicate TB testing in the preceding 12-month period.||Details|
|226||2022 Measure # 226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention||no||Process||Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within the measurement period AND who received tobacco cessation intervention on the date of the encounter or within the previous 12 months if identified as a tobacco user||Details|
|265||2022 Measure # 265 Biopsy Follow-Up||yes||Process||Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient.||Details|
|374||2022 Measure # 374 Closing the Referral Loop: Receipt of Specialist Report||yes||Process||Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred||Details|
|402||2022 Measure # 402 Tobacco Use and Help with Quitting Among Adolescents||no||Process||The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user||Details|
|410||2022 Measure # 410 Psoriasis: Clinical Response to Systemic Medications||yes||Outcome||Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient-reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment||Details|
Stay up to date with the latest news regarding MACRA and MIPS.
The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.